Dyne Therapeutics
http://www.dyne-tx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dyne Therapeutics
Judo Bio Emerges With $100m To Deliver siRNA Therapeutics To The Kidney
Judo Bio, incubated for three years by Atlas Venture to deliver siRNA and other genetic medicines to the kidney, came out of stealth mode with $100m and new CEO Rajiv Patni.
With FDA Hold Lifted, Avidity Works To Bring First DM1 Therapy To Market
Avidity hopes to complete enrollment in mid-2025 for an ongoing Phase III trial of its antibody-oligonucleotide conjugate in myotonic dystrophy type 1, which has no approved drug therapy.
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Dyne Reports Progress Building Next-Generation Exon Skipping Franchise In DMD
The company reported updated data from the Phase I/II DELIVER trial testing DYNE-251 in patients with Duchenne muscular dystrophy (DMD) and announced leadership changes.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice